SP Tulsian of sptulsian.com told CNBC-TV18, "Biocon probably for the last couple of months has been hitting new highs and honestly I am not convinced with this kind of valuations though it was lying subdued maybe for last couple of years. So sometime you see the bunched upmove also coming in this kind of stocks. I am not doubting about the fundamentals of the company, but the kind of run up which we have seen in the stock price maybe about more than 50 percent in this last maybe about six months or so. So you need to have some kind of caution, because maybe the trading momentum also comes into the play where you may see profit booking coming in. So, I will be having my cautious view on the stock at the current level."At 14:48 hrs Biocon was quoting at Rs 751.85, up Rs 41.70, or 5.87 percent. It has touched a 52-week high of Rs 762.00.The company's trailing 12-month (TTM) EPS was at Rs 40.44 per share. (Mar, 2016). The stock's price-to-earnings (P/E) ratio was 18.60. The latest book value of the company is Rs 164.38 per share. At current value, the price-to-book value of the company was 4.57. The dividend yield of the company was 0.66 percent.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
